興業證券:預計醫藥板塊業績將呈現邊際向好趨勢
興業證券8月5日研報表示,近期,醫藥板塊市場關注度逐步回升。回顧來看,醫藥板塊經歷2個多月的下行週期,自5月以來中信醫藥指數下行11.0%(截至8月2日收盤),同期滬深300指數下行6.1%,當前醫藥板塊估值和機構持倉均處於歷史低點。從業績端來看,綜合分析2023年Q2的業績基數及行業大環境等因素,我們預計2024年Q2板塊多數公司增長相對平穩,市場已有相應預期。近期業績預吿和中報陸續落地,多數公司符合預期,部分公司實現超預期,體現出醫藥板塊較強的業績韌性。展望下半年,行業大環境因素有望逐步改善,同時板塊將迎來業績基數下行階段,我們預計板塊業績將呈現邊際向好趨勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.